Drug Trial Radar · NCT07222878
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Sep 29, 2025
Primary completion
Nov 4, 2025
Study completion Nov 4, 2025
Sponsor
- Lead sponsor
- NeuroPro Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules
Conditions
- Epilepsy
- Alzheimer Disease
- Epilepsy Intractable
Interventions
NPT 2042 (Reference formula/Formulation 1)Drug
In Period 1 Day 1, participants will receive Formulation 1 in a fasted state (Treatment A).
NPT 2042 (Test formula/Formulation 2)Drug
Following a 3-day wash out, in Period 2 Day 1, participants will receive Formulation 2 in a fasted state (Treatment B).
NPT 2042 (Test formula/Formulation 2)Drug
Following a 4-day wash out, in Period 3 Day 1, participants will receive Formulation 2 in a fasted state with co-administered agent (Treatment C).
Primary outcomes
What the sponsor says the trial is designed to measure.
- To estimate the single dose pharmacokinetic parameters for each NPT 2042 formulation in healthy participants following each treatment.Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1), Tx. Period 2 (Day 4), and Tx. Period 3 (Day 7)
- To estimate the single dose pharmacokinetic parameters for each NPT 2042 formulation in healthy participants following each treatment.Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1), Tx. Period 2 (Day 4), and Tx. Period 3 (Day 7)
- To estimate the single dose pharmacokinetic parameters for each NPT 2042 formulation in healthy participants following each treatment.Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1), Tx. Period 2 (Day 4), and Tx. Period 3 (Day 7)
- To estimate the single dose pharmacokinetic parameters for each NPT 2042 formulation in healthy participants following each treatment.Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1), Tx. Period 2 (Day 4), and Tx. Period 3 (Day 7)
- To estimate the single dose pharmacokinetic parameters for each NPT 2042 formulation in healthy participants following each treatment.Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1), Tx. Period 2 (Day 4), and Tx. Period 3 (Day 7)
- To estimate the single dose pharmacokinetic parameters for each NPT 2042 formulation in healthy participants following each treatment.Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1), Tx. Period 2 (Day 4), and Tx. Period 3 (Day 7)
- To calculate the Frel and 90% confidence intervals for Formulation 1 (Reference) vs Formulation 2 (Test) both administered in a fasted state.Time frame: Baseline (Day -1) as compared to Tx. period 1 (Day 1) and Tx. Period 2 (Day 4)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion
Lincoln, Nebraska
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.